Seeking Alpha

the_value_vulture

the_value_vulture
Send Message
View as an RSS Feed
View the_value_vulture's Comments BY TICKER:
Latest  |  Highest rated
  • Theravance Is Now Providing Better Visibility [View article]
    Thanks ER,

    Well upon further investigation the THRX site offered some "help" with some form 8937's on the IR page. The January 8937 said the following related to both distribution of the spinoff AND the two dividends.

    "Based on reasonable assumptions currently available, of the total Distributions, approximately 40% Is expected to be taxable as
    a dividend and the remaining approximately 60% is expected to be a return of capital. Any amount considered a return of capital will reduce shareholder basis to the extent thereof. Any portion of the Distributions in excess of shareholder basis will be capital gain to the recipient shareholder."

    I'll probably end up talking to the IR department about this. Those that held should REALLY check their 1099s. I know mine's definitely not right.

    Disclosure: I am not a professional accountant. Please seek professional advice.
    Feb 21, 2015. 03:29 PM | 1 Like Like |Link to Comment
  • Theravance Is Now Providing Better Visibility [View article]
    Did anyone buy and hold THRX through the split between the royalty and biopharma? I am having a heck of a time understanding the split and whether the "dividend" received is indeed taxable or whether it is not because technically THRX in the year 2014 did not have accumulated earnings and profit. Any advice out there?

    " As a taxable transaction, an amount equal to the fair market value of the Theravance Biopharma ordinary shares received by you (including any fractional shares deemed to be received) on the distribution date will be treated as a taxable dividend to the extent of your ratable share of any current and accumulated earnings and profits of Theravance, measured as of the end of the year in which the distribution occurs, with the excess treated as a non-taxable return of capital to the extent of your tax basis in Theravance common stock and any remaining excess treated as a capital gain. "
    Feb 20, 2015. 10:18 PM | 1 Like Like |Link to Comment
  • Theravance: Notes From The Leerink Global Healthcare Conference [View article]
    Well looks like one head just rolled at GSK.

    GlaxoSmithKline has replaced the head of its North American business unit as it struggles to maintain sales in its biggest market.

    This is exactly what we need though considering the fumbling done already by insurance coverage of the respiratory portfolio.

    "Bailey's experience in dealing with healthcare payers is considered to a key factor behind the decision, with GSK's president of global pharmaceuticals Abbas Hussein saying the new head "is credited with successfully managing a rapidly changing healthcare environment, including the implementation of healthcare reform and an increased focus on the value of medicines."

    http://bit.ly/1L83Q0v
    Feb 17, 2015. 07:57 AM | 1 Like Like |Link to Comment
  • Theravance: Notes From The Leerink Global Healthcare Conference [View article]
    I have to write that one down.
    Feb 13, 2015. 05:56 PM | 1 Like Like |Link to Comment
  • Dip-buyers continue to head into energy [View news story]
    Rig count is collapsing but inventories are still ripping higher. There continues to be an expectation built in for a quick reversal in prices but there is nothing fundamental to warrant it. Unfortunately it looks like we are in the third inning and there desperately needs to be a few bankruptcies to weed out the continuous inventory build.
    Feb 11, 2015. 01:49 PM | 2 Likes Like |Link to Comment
  • HC2's New College Fund: Implications Of Separation Agreement Between Falcone And Harbinger Group [View article]
    Hi Stock reader.

    I know this question wasn't directed at me but maybe I could help. The two main companies that would be hurt by the plunge in the oil price would be ANG (American Natural Gas) and Global Marine Systems. I cannot find how much business GMS does for oil and gas in relation to the rest of their revenue but HC2 does specify this in their risk factors.

    "GMSL does significant business with clients in the oil and natural gas industry ... "

    Luckily ocean rigs are roaming around on multi year contracts. If oil stays down significantly for years revs will take a hit, but I don't think we need to worry yet.

    As far as construction is concerned, Schuff should be humming along just fine with the commercial construction coming back in a big way. Not to mention that we figured out what that big contract was that was announced at the end of September last year (the Giga-Factory) which has multiple phases that Schuff may end up with getting.

    If you read Brad's article on Nov 18th both Schuff and GMS were acquired at very advantageous pricing relative to public comparisons and other private party transactions.
    Feb 10, 2015. 09:56 PM | Likes Like |Link to Comment
  • Moonshot for Shake Shack, plan B for Five Guys and Smashburger? [View news story]
    This was great marketing on behalf of the investment banks and pump artists on various media outlets. Take a business concept which anyone can understand and then extrapolate the endless growth opportunity to the masses in an over saturated burger/shake/fries market. Investors are paying for years of future profits well in advance at these nosebleed prices.
    Jan 30, 2015. 10:54 AM | 7 Likes Like |Link to Comment
  • Samsung's Q4 earnings: Phones weak, chips and displays healthier [View news story]
    Bb10 can't even ignite blackberry sales. You want them on Samsung phones? Not a chance.

    Disclosure : z10 user
    Jan 28, 2015. 08:50 PM | 4 Likes Like |Link to Comment
  • Update: Theravance Reveals Interesting Bits Of Information At CS Conference [View article]
    Abdullah,

    Nice comment. The market is definitely providing an opportunity here. At closer to 10 a share or under I will probably find myself adding again.
    Jan 28, 2015. 06:52 PM | 2 Likes Like |Link to Comment
  • Update: Theravance Reveals Interesting Bits Of Information At CS Conference [View article]
    Chris,
    I think there are a couple of things to take into consideration. I believe the sales force issue to only be part of the problems surrounding the slow uptake of Breo and Anoro. Generally the US pharma market has changes significantly compared to when Advair launched. Everyone from the government to Express Scripts and CVS are starting to play hardball in regards to pricing. Commercial coverage of Breo and Anoro still stand at 64% and 78% respectively. Breo is more than a year into its launch! Although Theravance is looking like it may have another “dog” of a year, it looks like GSK will be turning up the heat on its respiratory portfolio from recent comments at the JPM Healthcare Conference.

    With almost 1 year down in my 2 to 4 year investment timeline, I think THRX becomes a comeback kid by 2H of 2015.

    http://bit.ly/1CA3pJr

    “Last year, GlaxoSmithKline's ($GSK) Breo and Anoro--respiratory drugs meant to step in for aging giant Advair--got off to a sluggish start. Entering 2015, you don't need to tell the British drugmaker what needs to happen. It expects Advair to be a "an ongoing drag" as its sales decline 20% to 25% in the U.S., Chief Strategy Officer David Redfern said late Tuesday afternoon, and "it's really the year where we have to make significant progress shifting the business … into the much broader portfolio." That'll involve taking advantage of increased Medicare Part D coverage for the newcomer duo, with Breo now boasting 76% coverage and Anoro 65%. "We're in a much better position" in 2015 than in 2014, Redfern said, and "clearly one of our big challenges through the first part of this year and through '15 is to convert that greater access to real scripts and to real business and build momentum behind these brands." Slides”
    Jan 28, 2015. 05:39 PM | 2 Likes Like |Link to Comment
  • Update: Theravance Reveals Interesting Bits Of Information At CS Conference [View article]
    Chris

    I'm a little confused here. Where are you getting $20M for the quarter in total? Breo alone in Q3 did $25M and that was with a lot less in prescriptions.

    Also it's 15% for Breo currently but Anoro around 6.5%.
    Jan 28, 2015. 04:55 PM | 1 Like Like |Link to Comment
  • Update: Theravance Reveals Interesting Bits Of Information At CS Conference [View article]
    Anyone look at the latest THRX presentation on the thrxinc.com site?

    Highlights

    - Looks like RX volume on both Breo and Anoro continue to increase albeit still at a slow pace. New prescriptions for both were in the mid 40% range.
    - Medicare part D coverage 76% Breo / 65% Anoro
    - anticipate to hear Breo's asthma approval by end of April

    Also keep in mind the Breo forumlary moves for CVS and Express Scripts started this month.

    In the meantime THRX stock continues to scrape the bottom of the barrel near 52 week lows.
    Jan 27, 2015. 08:17 PM | 2 Likes Like |Link to Comment
  • Futures sink following Greek elections [View news story]
    Can the common Greek citizen not see through what is begin promised? A politician wants to increase social welfare, reinstate many of the pension and wage cuts, increase the minimum wage, renegotiate the debt it owes creditors, and all while staying in the eurozone. Do these people have a third world education or is it just complete desperation?

    I mean what is the bargaining chip at this point that will create a happy ending for the Greeks? Without the euro, 25% unemployment and the current economic upheaval will look like a speed bump compared to what is in store.
    Jan 25, 2015. 10:22 PM | 9 Likes Like |Link to Comment
  • HC2 Receives $9.7 Million Dividend From Its Subsidiary Global Marine and Issues $14 Million of Preferred Stock [View article]
    Sounds like another acquisition is on the horizon. Big opportunities in the oil and gas space. Plenty of smaller players looking at some serious cash constraints and unmanageable debt loads.
    Jan 11, 2015. 08:44 PM | Likes Like |Link to Comment
  • My 2015 Value Stock Picks [View article]
    This is a little brash and extremely unfair. Calling out an investor on their one year performance? Really? Anyone who has been in the game long enough has had a setback. Some of the best investors have suffered underperformance vs the S&P index at various points in their investment career.

    True performance can only really be measured over the course of a 5 or 10 year period with a recession or two in the mix. Please save your childish responses for the yahoo boards.
    Jan 4, 2015. 10:52 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
221 Comments
544 Likes